Researchers reported a systemic, non-viral strategy for delivering full-length DMD mRNA using skeletal-muscle-targeted extracellular vesicles (EVs) engineered with targeting tags. In a murine DMD model, the approach restored dystrophin production and improved muscle strength and function. The work also included translational support, showing safety and biocompatibility in non-human primates—an important step for non-viral platforms that aim to avoid viral vector constraints. The study was published in Nature Biomedical Engineering. By tackling the size limitations of the DMD gene for viral vectors, the platform targets a core barrier to bringing gene-based therapies into broader clinical use, potentially enabling full-gene payload delivery with a different safety and redosing profile.